Tacrine, (9-amino-1,2,3,4-tetrahydroacridine), an especially well-known acridine-based cholinesterase inhibitor, was the first FDA-approved drug for the treatment of the cognitive symptoms of AD (Crismon, 1994). This evidence concerns the gene BCHE and Alzheimer disease.